Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro.
None
CYP3As
DAA
HCV
LC-MS/MS
human liver microsomes
metabolism
pharmacogenetics
Journal
Xenobiotica; the fate of foreign compounds in biological systems
ISSN: 1366-5928
Titre abrégé: Xenobiotica
Pays: England
ID NLM: 1306665
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
pubmed:
20
9
2018
medline:
24
12
2019
entrez:
20
9
2018
Statut:
ppublish
Résumé
Paritaprevir (PTV) is a non-structural protein 3/4A protease inhibitor developed for the treatment of hepatitis C disease as a fixed dose combination of ombitasvir (OBV) and ritonavir (RTV) with or without dasabuvir. The aim of this study was to evaluate the effects of cytochrome P450 (CYP) 3A5 on in vitro PTV metabolism using human recombinant CYP3A4, CYP3A5 (rCYP3A4, rCYP3A5) and human liver microsomes (HLMs) genotyped as either CYP3A5*1/*1, CYP3A5*1/*3 or CYP3A5*3/*3. The intrinsic clearance (CL
Identifiants
pubmed: 30227770
doi: 10.1080/00498254.2018.1524947
doi:
Substances chimiques
Anilides
0
Carbamates
0
Cyclopropanes
0
Lactams, Macrocyclic
0
Macrocyclic Compounds
0
Protease Inhibitors
0
Sulfonamides
0
ombitasvir
2302768XJ8
Proline
9DLQ4CIU6V
CYP3A5 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP3A
EC 1.14.14.1
CYP3A4 protein, human
EC 1.14.14.55
Valine
HG18B9YRS7
paritaprevir
OU2YM37K86
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM